COPDおよび喘息装置の世界市場2020–2027:製品種類別(吸入器、ネブライザー)、疾患別、流通チャンネル別

◆英語タイトル:COPD and Asthma Devices Market by Product Type (Inhalers and Nebulizers), Indication (Asthma and COPD), and Distribution Channel (Retail Pharmacies, Hospitals, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast 2020–2027
◆商品コード:AMR20PL029
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2020年6月
◆ページ数:276
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD5,769 ⇒換算¥605,745見積依頼/購入/質問フォーム
5 UserUSD6,450 ⇒換算¥677,250見積依頼/購入/質問フォーム
Enterprise UserUSD8,995 ⇒換算¥944,475見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査レポートでは、COPDおよび喘息装置の世界市場について調査・分析することにより、イントロダクション、エグゼクティブサマリー、市場概要、製品種類別(吸入器、ネブライザー)分析、疾患別分析、流通チャンネル別分析、地域別分析、企業情報など、今後の市場展望をまとめております。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・COPDおよび喘息装置の世界市場規模:製品種類別(吸入器、ネブライザー)
・COPDおよび喘息装置の世界市場規模:疾患別
・COPDおよび喘息装置の世界市場規模:流通チャンネル別
・COPDおよび喘息装置の世界市場規模:地域別
・企業情報

【レポートの概要】

The global COPD and asthma devices market is expected to reach $51,628.58 million by 2027, registering a CAGR of 4.30% during 2020-2027.

Chronic obstructive pulmonary disease (COPD) and asthma devices, also known as pulmonary drug delivery devices, are used as a permanent treatment or rescue therapy for respiratory diseases and other related ailments. It is the most advanced mode of drug administration in which the drug is directly delivered to the lungs to provide a systemic effect. COPD and asthma have significant shares in the global respiratory diseases market. According to the Global Health Organization (WHO), in 2016, around 251 million cases of COPD were estimated globally. Thus, a variety of drug-delivery protocols, such as oral and parenteral delivery, are developed for the treatment of COPD and asthma. However, the pulmonary drug delivery system is the most effective treatment option as compared to the other conventional methods.

The major factors that drive the market growth are increase in concerns of respiratory diseases, such as asthma and emphysema, and rise in incidences of respiratory diseases caused due to cigarette consumption. Furthermore, increase in healthcare expenditure, growth in use of automation in the healthcare industry, and rapid adoption of advanced medical solutions also boost the market growth. Currently, most of healthcare practitioners and pulmonary diseases specialists prefer a combination of a drug and a device, for instance, inhaler and nebulizer, owing to its fast and effective outcome. However, the factors such as high cost associated with nebulizers, side effects occurring due to excessive dosage, and lack of awareness regarding the drug inhalation are expected to restrain the growth of the market. On the contrary, introduction of smart inhaler drives the opportunity for the growth of COPD and asthma devices market in near future.

The global COPD and asthma devices market is segmented on the basis of product type, indication, distributional channel, and region. Based on the device type, the market is segmented into inhalers and nebulizers. Furthermore, the inhalers segment includes dry powder inhalers (DPIs), metered dose inhalers (MDIs), and soft mist inhalers (SMIs). However, the nebulizers segment includes compressor nebulizers, ultrasonic nebulizers, and mesh nebulizers. Based on indication, the market is divided into asthma and COPD. Based on distribution channel, it is segregated into retail pharmacies, online pharmacies, and hospitals. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA. These regions are further analyzed on the basis of respective countries.

The leading players profiled in this report include Aerogen, Inc., AstraZeneca PLC, Baxter International Inc., Boehringer Ingelheim International GmbH, 3M COMPANY, GF Health Products, GlaxoSmithKline Plc, Koninklijke Philips N.V., Novartis AG, PARI Medical Holding GMBH, and Smith’s Group Plc.

KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current global antihypertensive market trends from 2019 to 2027 to identify the prevailing opportunities along with the strategic assessment.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

Key Market Segments
By Product Type
• Inhalers
o Drug Powder Inhalers (DPIs)
o Metered Dose Inhalers (MDIs)
o Soft Mist Inhalers (SMIs)
• Nebulizers
o Compressor Nebulizers
o Ultrasonic Nebulizers
o Mesh Nebulizers

By Indication
o Asthma
o COPD

By Distribution Channel
o Retail Pharmacies
o Hospitals
o Online Pharmacies

• By Region
o North America
§ U.S.
§ Canada
§ Mexico
o Europe
§ Germany
§ France
§ UK
§ Italy
§ Russia
§ Rest of Europe
o Asia-Pacific
§ Japan
§ China
§ India
§ Australia
§ Rest of Asia-Pacific
o Middle East
§ Saudi Arabia
§ Brazil
§ Argentina
§ Colombia
§ Turkey
§ Rest of LAMEA

List of key players profiled in the report
• Aerogen, Inc.
• AstraZeneca PLC
• Baxter International Inc.
• Boehringer Ingelheim International GmbH
• 3M COMPANY
• GF Health Products
• GlaxoSmithKline Plc
• Koninklijke Philips N.V.
• Novartis AG
• PARI Medical Holding GMBH
• Smith’s Group Plc.

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
• Lincare Holdings Inc
• Allied Healthcare Products Inc
• Sunovion Pharmaceuticals Inc

【レポートの目次】

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits
1.3.Key market segments
1.4.Research methodology

1.4.1.Primary research
1.4.2.Secondary Research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.key findings of the study:
2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top impacting factors
3.2.2.Top investment pockets
3.2.3.Top winning strategies, 2016-2018

3.3.Porter’s five forces analysis

3.3.1.Moderate bargaining power of buyers
3.3.2.Low bargaining power of suppliers
3.3.3.Moderate threat of substitutes
3.3.4.Low threat of new entrants
3.3.5.Moderate competitive rivalry

3.4.Value chain analysis
3.5.Government regulations

3.5.1.COPD devices regulations in Europe and in the U.S.
3.5.2.COPD devices regulations in Asia-Pacific

3.6.Clinical trials
3.7.Patent analysis

3.7.1.Patent analysis by region
3.7.2.U.S. Patent analysis
3.7.3.Europe patent analysis
3.7.4.Japan patent analysis

3.8.Drivers

3.8.1.Daily exposure to environmental pollution
3.8.2.Increase in population susceptible to indoor air pollutants
3.8.3.Portability of the drug delivery devices
3.8.4.Increasing population of active smokers
3.8.5.Rising government initiatives

3.9.Restraints

3.9.1.Increase in price competition and deterioration of material quality
3.9.2.Overall high cost of asthma treatment is a challenge for the patients
3.9.3.Incompetent reimbursement support

3.10.Opportunities

3.10.1.Patent expiration for blockbuster drugs
3.10.2.Smart Inhaler: future growth driver

CHAPTER 4:COPD AND ASTHMA DEVICES MARKET, BY PRODUCT

4.1.Overview

4.1.1.Market size and forecast

4.2.Inhalers

4.2.1.Market size and forecast
4.2.2.Market share analysis, by country
4.2.3.Drug powdered inhalers (DPIs)

4.2.3.1.Key market trends and opportunity

4.2.4.Metered dose inhalers (MDIs)

4.2.4.1.Key market trends and opportunity

4.2.5.Soft mist inhalers

4.2.5.1.Key market trends and opportunity

4.3.Nebulizers

4.3.1.Market size and forecast
4.3.2.Market share analysis, by country

4.3.2.1.Compressor nebulizers
4.3.2.2.Ultrasonic nebulizers
4.3.2.3.Mesh nebulizers

CHAPTER 5:COPD AND ASTHMA DEVICES MARKET, BY INDICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Asthma

5.2.1.Market size and forecast
5.2.2.Market share analysis, by country

5.3.COPD

5.3.1.Market size and forecast
5.3.2.Market share analysis, by country

CHAPTER 6:COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL

6.1.Overview

6.1.1.Market size and forecast

6.2.Retail Pharmacies

6.2.1.Market size and forecast
6.2.2.Market share analysis, by country

6.3.Hospitals

6.3.1.Market size and forecast
6.3.2.Market share analysis, by country

6.4.Online Pharmacies

6.4.1.Market size and forecast
6.4.2.Market share analysis, by country

CHAPTER 7:COPD & ASTHMA DEVICE MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends and opportunities
7.2.2.North America market size and forecast, by country
7.2.3.North America market size and forecast, by product
7.2.4.North America market size and forecast, by indication
7.2.5.North America market size and forecast, by distribution channel

7.2.5.1.U.S.

7.2.5.1.1.U.S. market size and forecast, by product
7.2.5.1.2.U.S. market size and forecast, by indication
7.2.5.1.3.U.S. market size and forecast, by distribution channel

7.2.5.2.Canada

7.2.5.2.1.Canada market size and forecast, by product
7.2.5.2.2.Canada market size and forecast, by indication
7.2.5.2.3.Canada market size and forecast, by distribution channel

7.2.5.3.Mexico

7.2.5.3.1.Mexico market size and forecast, by product
7.2.5.3.2.Mexico market size and forecast, by indication
7.2.5.3.3.Mexico market size and forecast, by distribution channel

7.3.Europe

7.3.1.Key market trends and opportunities
7.3.2.Europe market size and forecast, by country
7.3.3.Europe market size and forecast, by product
7.3.4.Europe market size and forecast, by indication
7.3.5.Europe market size and forecast, by distribution channel

7.3.5.1.Germany

7.3.5.1.1.Germany market size and forecast, by product
7.3.5.1.2.Germany market size and forecast, by indication
7.3.5.1.3.Germany market size and forecast, by distribution channel

7.3.5.2.UK

7.3.5.2.1.UK market size and forecast, by product
7.3.5.2.2.UK market size and forecast, by indication
7.3.5.2.3.UK market size and forecast, by distribution channel

7.3.5.3.France

7.3.5.3.1.France market size and forecast, by product
7.3.5.3.2.France market size and forecast, by indication
7.3.5.3.3.France market size and forecast, by distribution channel

7.3.5.4.Italy

7.3.5.4.1.Italy market size and forecast, by product
7.3.5.4.2.Italy market size and forecast, by indication
7.3.5.4.3.Italy market size and forecast, by distribution channel

7.3.5.5.Russia

7.3.5.5.1.Russia market size and forecast, by product
7.3.5.5.2.Russia market size and forecast, by indication
7.3.5.5.3.Russia market size and forecast, by distribution channel

7.3.5.6.Rest of Europe

7.3.5.6.1.Rest of Europe market size and forecast, by product
7.3.5.6.2.Rest of Europe market size and forecast, by indication
7.3.5.6.3.Rest of Europe market size and forecast, by distribution channel

7.4.Asia-Pacific

7.4.1.Key market trends and opportunities
7.4.2.Asia-Pacific market size and forecast, by country
7.4.3.Asia-Pacific market size and forecast, by product
7.4.4.Asia-Pacific market size and forecast, by indication
7.4.5.Asia-Pacific market size and forecast, by distribution channel

7.4.5.1.Japan

7.4.5.1.1.Japan market size and forecast, by product
7.4.5.1.2.Japan market size and forecast, by indication
7.4.5.1.3.Japan market size and forecast, by distribution channel

7.4.5.2.China

7.4.5.2.1.China market size and forecast, by product
7.4.5.2.2.China market size and forecast, by indication
7.4.5.2.3.China market size and forecast, by distribution channel

7.4.5.3.India

7.4.5.3.1.India market size and forecast, by product
7.4.5.3.2.India market size and forecast, by indication
7.4.5.3.3.India market size and forecast, by distribution channel

7.4.5.4.Australia

7.4.5.4.1.Australia market size and forecast, by product
7.4.5.4.2.Australia market size and forecast, by indication
7.4.5.4.3.Australia market size and forecast, by distribution channel

7.4.5.5.Rest of Asia-Pacific

7.4.5.5.1.Rest of Asia-Pacific market size and forecast, by product
7.4.5.5.2.Rest of Asia-Pacific market size and forecast, by indication
7.4.5.5.3.Rest of Asia-Pacific market size and forecast, by distribution channel

7.5.LAMEA

7.5.1.Key market trends and opportunities
7.5.2.LAMEA market size and forecast, by country
7.5.3.LAMEA market size and forecast, by product
7.5.4.LAMEA market size and forecast, by indication
7.5.5.LAMEA market size and forecast, by distribution channel

7.5.5.1.Brazil

7.5.5.1.1.Brazil market size and forecast, by product
7.5.5.1.2.Brazil market size and forecast, by indication
7.5.5.1.3.Brazil market size and forecast, by distribution channel

7.5.5.2.Argentina

7.5.5.2.1.Argentina market size and forecast, by product
7.5.5.2.2.Argentina market size and forecast, by indication
7.5.5.2.3.Argentina market size and forecast, by distribution channel

7.5.5.3.Saudi Arabia

7.5.5.3.1.Saudi Arabia market size and forecast, by product
7.5.5.3.2.Saudi Arabia market size and forecast, by indication
7.5.5.3.3.Saudi Arabia market size and forecast, by distribution channel

7.5.5.4.Colombia

7.5.5.4.1.Colombia market size and forecast, by product
7.5.5.4.2.Colombia market size and forecast, by indication
7.5.5.4.3.Colombia market size and forecast, by distribution channel

7.5.5.5.Turkey

7.5.5.5.1.Turkey market size and forecast, by product
7.5.5.5.2.Turkey market size and forecast, by indication
7.5.5.5.3.Turkey market size and forecast, by distribution channel

7.5.5.6.Rest of LAMEA

7.5.5.6.1.Rest of LAMEA market size and forecast, by product
7.5.5.6.2.Rest of LAMEA market size and forecast, by indication
7.5.5.6.3.Rest of LAMEA market size and forecast, by distribution channel

CHAPTER 8:COMPANY PROFILES

8.1.Aerogen, Inc.

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Product portfolio

8.2.AstraZeneca PLC

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance
8.2.6.Key strategic moves and developments

8.3.Baxter International Inc.

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product Portfolio
8.3.5.Business performance

8.4.Boehringer Ingelheim International GmbH

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance

8.5.3M COMPANY

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments

8.6.GF Health Products, Inc.

8.6.1.Company overview
8.6.2.Product portfolio

8.7.GlaxoSmithKline Plc

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance
8.7.6.Key strategic moves and developments

8.8.Koninklijke Philips N.V. (Philips)

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.8.6.Key strategic moves and developments

8.9.Novartis AG

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance
8.9.6.Key strategic moves and developments

8.10.PARI medical Holding GMBH

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Key strategic moves and developments

8.11.Smith’s Group Plc

8.11.1.Company overview
8.11.2.Company snapshot
8.11.3.Operating business segments
8.11.4.Product portfolio
8.11.5.Business performance

LIST OF TABLES

TABLE 01.CLINICAL TRIALS - COPD AND ASTHMA DEVICES
TABLE 02.COPD AND ASTHMA DEVICES PATENTS
TABLE 03.ADVANTAGES AND DISADVANTAGES OF MARKETED PORTABLE INHALER DEVICES
TABLE 04.PERCENTAGE OF SMOKER POPULATION BY RACE/ETHNICITY, 2016
TABLE 05.COST OF ASTHMA IN BILLION, 2015
TABLE 06.COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019-2027 ($MILLION)
TABLE 07.RESCUE INHALERS VS MAINTENANCE INHALERS
TABLE 08.COMMON TYPES OF INHALERS
TABLE 09.TOP 10 COPD INHALERS
TABLE 10.INHALERS COPD AND ASTHMA DEVICES MARKET, BY REGION 2019-2027, ($MILLION)
TABLE 11.DRY POWDER INHALERS
TABLE 12.TYPES OF METERED DOSE INHALERS (MDIS)
TABLE 13.COMMERCIALIZED NEBULIZERS AND ITS COST
TABLE 14.NEBULIZERS COPD AND ASTHMA DEVICES MARKET, BY REGION 2019-2027, ($MILLION)
TABLE 15.COPD AND ASTHMA DEVICES MARKET, BY APPLICATION, 2019-2027 ($MILLION)
TABLE 16.ASTHMA COPD ANDS ASTHMA DEVICES MARKET, BY REGION, 2019-2027 ($MILLION)
TABLE 17.COPD AND ASTHMA DEVICES MARKET, BY REGION, 2019-2027 ($MILLION)
TABLE 18.COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 ($MILLION)
TABLE 19.RETAIL PHARMACIES COPD AND ASTHMA DEVICES MARKET, BY REGION, 2019-2027 ($MILLION)
TABLE 20.HOSPITALS COPD AND ASTHMA DEVICES MARKET, BY REGION, 2019-2027 ($MILLION)
TABLE 21.ONLINE PHARMACIES COPD AND ASTHMA DEVICES MARKET, BY REGION, 2019-2027 ($MILLION)
TABLE 22.GLOBAL COPD AND ASTHMA DEVICES MARKET, BY REGION 2019-2027 ($MILLION)
TABLE 23.NORTH AMERICA COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 24.NORTH AMERICA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 25.NORTH AMERICA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 26.NORTH AMERICA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 27.U.S. COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 28.U.S. COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 29.U.S. COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 30.CANADA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 31.CANADA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 32.CANADA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 33.MEXICO COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 34.MEXICO COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 35.MEXICO COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 36.EUROPE COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 37.EUROPE COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 38.EUROPE COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 39.GERMANY COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 40.GERMANY COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 41.GERMANY COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 42.UK COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 43.UK COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 44.UK COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 45.FRANCE COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 46.FRANCE COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 47.FRANCE COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 48.ITALY COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 49.ITALY COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 50.ITALY COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 51.RUSSIA COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 52.RUSSIA COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 53.RUSSIA COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 54.REST OF EUROPE COPD AND ASTHMA DEVICESMARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 55.REST OF EUROPE COPD AND ASTHMA DEVICESMARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 56.REST OF EUROPE COPD AND ASTHMA DEVICESMARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 57.ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 58.ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 59.ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 60.ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 61.JAPAN COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 62.JAPAN COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 63.JAPAN COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 64.CHINA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 65.CHINA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 66.CHINA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 67.INDIA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 68.INDIA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 69.INDIA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 70.AUSTRALIA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 71.AUSTRALIA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 72.AUSTRALIA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 73.REST OF ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 74.REST OF ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 75.REST OF ASIA-PACIFIC COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 76.LAMEA COPD AND ASTHMA DEVICES MARKET, BY COUNTRY, 2019–2027 ($MILLION)
TABLE 77.LAMEA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 78.LAMEA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 79.LAMEA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 80.BRAZIL COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 81.BRAZIL COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 82.BRAZIL COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 83.ARGENTINA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 84.ARGENTINA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 85.ARGENTINA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 86.SAUDI ARABIA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 87.SAUDI ARABIA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 88.SAUDI ARABIA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 89.COLOMBIA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 90.COLOMBIA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 91.COLOMBIA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 92.TURKEY COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 93.TURKEY COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 94.TURKEY COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 95.REST OF LAMEA COPD AND ASTHMA DEVICES MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 96.REST OF LAMEA COPD AND ASTHMA DEVICES MARKET, BY INDICATION, 2019–2027 ($MILLION)
TABLE 97.REST OF LAMEA COPD AND ASTHMA DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2019–2027 ($MILLION)
TABLE 98.AEROGEN: COMPANY SNAPSHOT
TABLE 99.AEROGEN: PRODUCT PORTFOLIO
TABLE 100.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 101.ASTRAZENECA: OPERATING SEGMENTS
TABLE 102.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 01.BAXTER: COMPANY SNAPSHOT
TABLE 02.BAXTER: BUSINESS UNITS
TABLE 03.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
TABLE 04.BOEHRINGER INGELHEIM: PRODUCT BUSINESS SEGMENTS
TABLE 05.BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO
TABLE 06.3M: COMPANY SNAPSHOT
TABLE 07.3M: OPERATING BUSINESS SEGMENTS
TABLE 08.3M: PRODUCT PORTFOLIO
TABLE 09.GF HEALTH PRODUCTS: SNAPSHOT
TABLE 10.GF HEALTH PRODUCTS: PRODUCT PORTFOLIO
TABLE 11.GSK.: COMPANY SNAPSHOT
TABLE 12.GSK: OPERATING SEGMENTS
TABLE 13.GSK: PRODUCT PORTFOLIO
TABLE 14.PHILIPS: COMPANY SNAPSHOT
TABLE 15.PHILIPS: OPERATING SEGMENTS
TABLE 16.PHILIPS: PRODUCT PORTFOLIO
TABLE 17.NOVARTIS: COMPANY SNAPSHOT
TABLE 18.NOVARTIS: OPERATING SEGMENTS
TABLE 19.NOVARTIS: PRODUCT PORTFOLIO
TABLE 20.PARI: COMPANY SNAPSHOT
TABLE 21.PARI: PRODUCT PORTFOLIO
TABLE 22.PARI: PRODUCT PORTFOLIO
TABLE 23.SMITHS MEDICAL: COMPANY SNAPSHOT
TABLE 24.SMITHS MEDICAL: OPERATING SEGMENTS
TABLE 25.SMITHS MEDICAL: PRODUCT PORTFOLIOG

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[COPDおよび喘息装置の世界市場2020–2027:製品種類別(吸入器、ネブライザー)、疾患別、流通チャンネル別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆